Abstract
Patients treated for early breast cancer have only a 10–15% probability of local relapse (Fowble, 1991), but the likelihood of eventual recurrence with distant metastases can be much higher depending on the original stage of the cancer. It is from this systemic disease that patients die (Willner et al., 1997). Treatment of malignant tumors has relied heavily on the use of cytotoxic agents, targeted at the increased metabolic and proliferative activity of the cancer cell. An alternative strategy has been to develop low toxicity therapies that can be administered continuously over a period of several years to stabilize malignant disease, and it is in this category that treatment with matrix metallopro-teinase inhibitors (MMPIs) lie.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call